# A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

> **NCT01047007** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 11 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** adavosertib 20 mg
- **DRUG:** 5-FU 1000 mg/m^2/day
- **DRUG:** CDDP
- **DRUG:** adavosertib 65 mg

## Key facts

- **NCT ID:** NCT01047007
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01-18
- **Primary completion:** 2011-06-15
- **Final completion:** 2011-06-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The study has been terminated due to business reasons.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047007, "A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01047007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*